Endothelial Progenitor Cell Labeling Service

Endothelial Progenitor Cell Labeling Service

Unleash the Potential of Precision Endothelial Progenitor Cell (EPC) Labeling

EPCs are a type of stem cell with the potential to differentiate from vascular endothelial cells. They can differentiate into mature endothelial cells that participate in the process of vascular neovascularization and repair. At CD BioGlyco, we provide professional GlycoCLICK™-based Labeling Service, including our efficient EPC labeling service. Our purpose in providing EPC labeling service is to enable their non-invasive imaging and tracking and help research observing their migration and localization in vivo in real time, to understand their distribution in ischemic tissues, as well as to assess their therapeutic efficacy and biological mechanisms.

  • First, we introduce clickable chemical groups such as azides, alkynes, thiols, and ketones to the cell surface by metabolic sugar engineering.
  • Our experts then utilize copper-free click chemistry to chemically label clickable chemical groups on the cell surface with bioorthogonal imaging probes containing fluorescent dyes and multimodal imaging probes. In this way, cells are efficiently labeled with various imaging probes without significantly affecting their viability, proliferation, or differentiation. Conventional labeling agents such as DiI and Hoechst dyes can be toxic and functionally damaging to stem cells, whereas our technique does not have significant toxic effects on cells.

Process of EPC labeling. (CD BioGlyco)

Publication Data

Technology: Fluorescence molecular tomography (FMT)

Journal: Biomaterials

IF: 15.304

Published: 2021

Results: This article investigates the therapeutic efficacy of EPCs labeled by bioorthogonal click chemistry and metabolic glycoengineering in a model of therapeutic lower limb ischemia and predicts the therapeutic efficacy of the cells by non-invasive FMT imaging methods. This labeling strategy offers the advantages of greater safety, long-term tracking ability, and efficiency. Non-invasive tracking of stem cells is achieved by generating unnatural azide groups on the stem cell surface through Ac4ManNAz pretreatment and using a fluorescent dye-coupled clickable imaging probe to specifically bind to the azide groups on the surface of human embryonic stem cells-derived EPCs (hEPCs) via bioorthogonal click chemistry. This does not cause cytotoxicity and functionally perturbs the renal tubule formation, oxygen consumption, and paracrine effects of hEPC. This labeling and tracking strategy provides potential clues for predicting the efficacy of stem cell therapy for ischemic diseases.

Fig.1 Schematic illustration for the prediction of the effectiveness of bioorthogonally labeled hEPCs in a hind limb ischemia model using non-invasive FMT imaging.Fig.1 Schematic for predicting how well bioorthogonally labeled hEPCs work in a hind limb ischemia model using non-invasive FMT imaging. (Lim, et al., 2021)

Applications

  • EPC labeling can be used to label tumor cells to enable assessment of their migration and spreading effects in vivo.
  • This technology is used to label neurons and neural stem cells to enable their tracking in vivo and to study processes such as neural development and repair.
  • EPC labeling technology can be used to assess the toxicological and pharmacokinetic properties of drugs. Quantification of labeled EPCs allows measurement of the effects of drugs on their proliferation, survival, and differentiation, as well as on vascular regeneration and repair functions.

Advantages

  • Labeled cells can be tracked in vivo for extended periods. This allows researchers to monitor the behavior and location of these cells over time, providing valuable insights into their function and potential applications.
  • This labeling strategy allows efficient labeling of a variety of imaging probes on cells without significantly altering their properties.
  • This labeling technique allows cells to be labeled using a variety of different imaging probes, enabling multimodal imaging and multiparametric analysis.

CD BioGlyco has always prioritized innovation and client satisfaction to provide our clients with industry-leading EPC labeling services. We are constantly exploring new technologies and processes to optimize our services while adhering to strict quality control measures to ensure product consistency and reliability. For further details, please don't hesitate to contact us.

Reference

  1. Lim, S.; et al. Predicting in vivo therapeutic efficacy of bioorthogonally labeled EPCs in hind limb ischemia models via non-invasive fluorescence molecular tomography. Biomaterials. 2021, 266: 120472.
For research use only. Not intended for any clinical use.
Related Services

Unleash the full potential of glycochemistry research with CD BioGlyco, the top CRO company committed to advancing the understanding of glycobiology through tailored solutions and exceptional expertise.

Copyright © CD BioGlyco. All Rights Reserved.
Top